Skip to main content
Top
Published in: International Journal of Hematology 5/2024

30-03-2024 | Myelodysplastic Syndrome | Images in Hematology

Faggot cells observed in a patient with myelodysplastic syndrome with increased blasts

Authors: Makoto Ito, Nobuaki Fukushima

Published in: International Journal of Hematology | Issue 5/2024

Login to get access

Excerpt

A 75-year-old woman was referred to our hospital for pancytopenia. An annual blood test performed by her primary care physician 2 months before her visit showed an abnormal blood count (WBC 2880/μL, Hb 10.3 g/dL, and Plt 14.2 × 104/μL). The patient was completely asymptomatic, without any bleeding symptoms. Blood tests conducted at our hospital yielded the following results: WBC 2200/μL (neutrophils 14%, lymphocytes 79%, and monocytes 7%), Hb 8.9 g/dL, Plt 14.5 × 104/μL, LDH 249 IU/L, PT 13.8 s, APTT 26.5 s, fibrinogen 270 mg/dL, and FDP < 5.0 μg/mL. Bone marrow aspiration revealed 11.5% myeloblasts and 3.5% promyelocytes with numerous Auer rods resembling faggot cells of acute promyelocytic leukemia (APL) (Figs. 1a–f). However, neutrophils containing bilobed nuclei with condensed chromatin (Pseudo-Pelger-Huet anomaly), micro-megakaryocytes, and dysplastic erythroblasts were also observed (Figs. 1g–i). Flow cytometry analysis revealed approximately 15% of blasts positive for CD13, CD33, CD34, and HLA-DR, which are atypical for classical APL (Supplementary Material). Polymerase chain reaction testing for PML::RARA yielded negative results, and G-banding and spectral karyotyping revealed the karyotype to be 46,XX,del(6)(q?)[15]/46, XX[5] (Supplementary Material). Based on these findings, myelodysplastic syndrome (MDS) with increased blasts was diagnosed, and azacytidine therapy was initiated. The patient responded to azacytidine and recovered from cytopenia. No faggot cells were observed during follow-up bone marrow aspiration. Although Auer rods are sometimes observed in patients with MDS, only one case of faggot cells in a patient with MDS has been reported, in which the faggot cells were transiently detected during follow-up [1]. This case demanded a careful diagnosis of MDS considering that faggot cells were detected from the initial bone marrow examination. One limitation of our report is that we were unable to test for the specific retinoic acid receptor rearrangement that causes variant APL. Since there were no evident differentiated cells with bundles of Auer rods, we considered two hypotheses: (1) that dysplastic cells and faggot cells (mainly myeloblasts and promyelocytes) were derived from the same clone, and (2) that two different disease-derived clones (i.e., APL and MDS) coexisted in the patient’s bone marrow. Although we could not completely rule out the coexistence of the variant APL with MDS, the absence of coagulopathy and the favorable response to azacytidine monotherapy appear to support our first hypothesis that the faggot cells were arising from MDS clones.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ogura H, Inagaki A, Wakita A. A case of myelodysplastic syndrome presenting with faggot-like cells. Int J Hematol. 2013;97:443–5.CrossRefPubMed Ogura H, Inagaki A, Wakita A. A case of myelodysplastic syndrome presenting with faggot-like cells. Int J Hematol. 2013;97:443–5.CrossRefPubMed
Metadata
Title
Faggot cells observed in a patient with myelodysplastic syndrome with increased blasts
Authors
Makoto Ito
Nobuaki Fukushima
Publication date
30-03-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Hematology / Issue 5/2024
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03767-3

Other articles of this Issue 5/2024

International Journal of Hematology 5/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine